Our Science

Powerful innovation to transform MS

We're committed to rigorous and ongoing evaluation.

Lower arterial cerebral blood flow is associated with worse neuroinflammation and immunomodulation composite proteomic scores

CXCL-13, CXCL-9 and IL-12 cerebrospinal fluid levels predict higher disease activity and are associated with intrathecal IgM synthesis in multiple sclerosis

Real-World Utilization of a Proteomic Biomarker Panel for Assessing Multiple Sclerosis Disease Activity in an Academic Multiple Sclerosis Clinic with a Diverse Patient Population

Interpretable Thalamic Volume Charts in Multiple Sclerosis

Disagreement Among Neuroradiologists Detecting Change in Multiple Sclerosis Disease Activity

Disease Activity Score and Disease Pathway Scores Measured Using the Multiple Sclerosis Disease Activity Test are Significantly Reduced Prior to the Week 96 Dose for Patients Treated with Ublituximab in the Phase 3 ULTIMATE I and II Studies

Clinical validation of a multi-protein, serum-based assay for disease activity assessments in multiple sclerosis

Longitudinal Robustness of Emergent MS Phenotypes from Multiprotein Serum

Robustness of Emergent Clusters from Multi-Protein Serum Data

Variability of Longitudinal Standard of Care Brain MRI Scans Ordered By a Single MS Center

1 2 3 4 … 9

Lower arterial cerebral blood flow is associated with worse neuroinflammation and immunomodulation composite proteomic scores

CXCL-13, CXCL-9 and IL-12 cerebrospinal fluid levels predict higher disease activity and are associated with intrathecal IgM synthesis in multiple sclerosis

Real-World Utilization of a Proteomic Biomarker Panel for Assessing Multiple Sclerosis Disease Activity in an Academic Multiple Sclerosis Clinic with a Diverse Patient Population

Interpretable Thalamic Volume Charts in Multiple Sclerosis

Disagreement Among Neuroradiologists Detecting Change in Multiple Sclerosis Disease Activity

Disease Activity Score and Disease Pathway Scores Measured Using the Multiple Sclerosis Disease Activity Test are Significantly Reduced Prior to the Week 96 Dose for Patients Treated with Ublituximab in the Phase 3 ULTIMATE I and II Studies

Clinical validation of a multi-protein, serum-based assay for disease activity assessments in multiple sclerosis

Longitudinal Robustness of Emergent MS Phenotypes from Multiprotein Serum

Robustness of Emergent Clusters from Multi-Protein Serum Data

Variability of Longitudinal Standard of Care Brain MRI Scans Ordered By a Single MS Center